Loading
A phase 3 trial of Belinostat and Pralatrexate in peripheral T-cell lymphomas, run by Acrotech Biopharma Inc., now recruiting.
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL is a phase 3 interventional study registered as NCT06072131 by Acrotech Biopharma Inc., with 504 participants planned, started 2023-10-04 and due to reach its primary completion in 2030-07. Interventions recorded: Belinostat Injection, Pralatrexate Injection, CHOP and COP.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Belinostat, Pralatrexate, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/